[{"orgOrder":0,"company":"UroGen Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Imiquimod","moa":"||Cytotoxic T-lymphocyte protein 4","graph1":"Oncology","graph2":"IND Enabling","graph3":"UroGen Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Solution","sponsorNew":"UroGen Pharma \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"UroGen Pharma \/ Undisclosed"},{"orgOrder":0,"company":"UroGen Pharma","sponsor":"The University of Texas MD Anderson Cancer Center","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Collaboration","leadProduct":"Imiquimod","moa":"||Cytotoxic T-lymphocyte protein 4","graph1":"Oncology","graph2":"IND Enabling","graph3":"UroGen Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Solution","sponsorNew":"UroGen Pharma \/ The University of Texas MD Anderson Cancer Center","highestDevelopmentStatusID":"5","companyTruncated":"UroGen Pharma \/ The University of Texas MD Anderson Cancer Center"},{"orgOrder":0,"company":"UroGen Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Imiquimod","moa":"Toll-like receptor 7","graph1":"Oncology","graph2":"Phase II","graph3":"UroGen Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"UroGen Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"UroGen Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Nantes University Hospital","sponsor":"Viatris","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Imiquimod","moa":"Toll-like receptor 7","graph1":"Oncology","graph2":"Phase III","graph3":"Nantes University Hospital","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Nantes University Hospital \/ Viatris","highestDevelopmentStatusID":"10","companyTruncated":"Nantes University Hospital \/ Viatris"},{"orgOrder":0,"company":"Maastricht University Medical Center","sponsor":"Viatris","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"NETHERLANDS","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Imiquimod","moa":"Toll-like receptor 7","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"Maastricht University Medical Center","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Cream","sponsorNew":"Maastricht University Medical Center \/ Viatris","highestDevelopmentStatusID":"10","companyTruncated":"Maastricht University Medical Center \/ Viatris"},{"orgOrder":0,"company":"Melanoma and Skin Cancer Trials Limited","sponsor":"Melanoma Institute Australia","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Imiquimod","moa":"Toll-like receptor 7","graph1":"Oncology","graph2":"Phase III","graph3":"Melanoma and Skin Cancer Trials Limited","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Melanoma and Skin Cancer Trials Limited \/ Melanoma Institute Australia","highestDevelopmentStatusID":"10","companyTruncated":"Melanoma and Skin Cancer Trials Limited \/ Melanoma Institute Australia"},{"orgOrder":0,"company":"Actavis Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"IRELAND","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Imiquimod","moa":"Toll-like receptor 7","graph1":"Dermatology","graph2":"Phase III","graph3":"Actavis Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Actavis Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Actavis Inc \/ Undisclosed"},{"orgOrder":0,"company":"Actavis Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"IRELAND","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Imiquimod","moa":"Toll-like receptor 7","graph1":"Dermatology","graph2":"Phase III","graph3":"Actavis Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Actavis Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Actavis Inc \/ Undisclosed"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Imiquimod","moa":"Toll-like receptor 7","graph1":"Dermatology","graph2":"Phase III","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Teva Pharmaceutical Industries \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Teva Pharmaceutical Industries \/ Undisclosed"},{"orgOrder":0,"company":"AIDS Malignancy Consortium","sponsor":"National Cancer Institute | The Emmes Company, LLC | University of Arkansas","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Imiquimod","moa":"Toll-like receptor 7","graph1":"Oncology","graph2":"Phase III","graph3":"AIDS Malignancy Consortium","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AIDS Malignancy Consortium \/ National Cancer Institute | The Emmes Company, LLC | University of Arkansas","highestDevelopmentStatusID":"10","companyTruncated":"AIDS Malignancy Consortium \/ National Cancer Institute | The Emmes Company, LLC | University of Arkansas"},{"orgOrder":0,"company":"AIDS Malignancy Consortium","sponsor":"National Cancer Institute | The Emmes Company, LLC | University of Arkansas | University of California, San Francisco | University of Arizona","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Imiquimod","moa":"Toll-like receptor 7","graph1":"Oncology","graph2":"Phase III","graph3":"AIDS Malignancy Consortium","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AIDS Malignancy Consortium \/ National Cancer Institute | The Emmes Company, LLC | University of Arkansas | University of California, San Francisco | University of Arizona","highestDevelopmentStatusID":"10","companyTruncated":"AIDS Malignancy Consortium \/ National Cancer Institute | The Emmes Company, LLC | University of Arkansas | University of California, San Francisco | University of Arizona"},{"orgOrder":0,"company":"Icahn School of Medicine at Mount Sinai","sponsor":"Bausch Health","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Imiquimod","moa":"Toll-like receptor 7","graph1":"Dermatology","graph2":"Phase II","graph3":"Icahn School of Medicine at Mount Sinai","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Icahn School of Medicine at Mount Sinai \/ Bausch Health","highestDevelopmentStatusID":"8","companyTruncated":"Icahn School of Medicine at Mount Sinai \/ Bausch Health"},{"orgOrder":0,"company":"MEDICIS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Imiquimod","moa":"Toll-like receptor 7","graph1":"Dermatology","graph2":"Phase IV","graph3":"MEDICIS","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"MEDICIS \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"MEDICIS \/ Undisclosed"},{"orgOrder":0,"company":"Taro Pharmaceutical Industries","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Imiquimod","moa":"Toll-like receptor 7","graph1":"Dermatology","graph2":"Phase I","graph3":"Taro Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Taro Pharmaceutical Industries \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Taro Pharmaceutical Industries \/ Undisclosed"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Imiquimod","moa":"Toll-like receptor 7","graph1":"Oncology","graph2":"Phase I","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Washington University School of Medicine \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"Washington University School of Medicine \/ Merck & Co"},{"orgOrder":0,"company":"Viatris","sponsor":"SIRO Clinpharm | Accovion","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Imiquimod","moa":"Toll-like receptor 7","graph1":"Dermatology","graph2":"Phase IV","graph3":"Viatris","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Sachet","sponsorNew":"Viatris \/ SIRO Clinpharm | Accovion","highestDevelopmentStatusID":"11","companyTruncated":"Viatris \/ SIRO Clinpharm | Accovion"},{"orgOrder":0,"company":"Moberg Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Imiquimod","moa":"Toll-like receptor 7","graph1":"Dermatology","graph2":"Phase II","graph3":"Moberg Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Moberg Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Moberg Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Moberg Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Imiquimod","moa":"Toll-like receptor 7","graph1":"Undisclosed","graph2":"Phase I","graph3":"Moberg Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Moberg Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Moberg Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Barretos Cancer Hospital","sponsor":"Farmoquimica","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"BRAZIL","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Imiquimod","moa":"Toll-like receptor 7","graph1":"Oncology","graph2":"Phase II","graph3":"Barretos Cancer Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Barretos Cancer Hospital \/ Farmoquimica","highestDevelopmentStatusID":"8","companyTruncated":"Barretos Cancer Hospital \/ Farmoquimica"},{"orgOrder":0,"company":"Barretos Cancer Hospital","sponsor":"FAPESP | Farmoquimica | Hospital de Cancer de Barretos - Fundacao Pio XII","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"BRAZIL","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Imiquimod","moa":"Toll-like receptor 7","graph1":"Oncology","graph2":"Phase IV","graph3":"Barretos Cancer Hospital","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Barretos Cancer Hospital \/ FAPESP | Farmoquimica | Hospital de Cancer de Barretos - Fundacao Pio XII","highestDevelopmentStatusID":"11","companyTruncated":"Barretos Cancer Hospital \/ FAPESP | Farmoquimica | Hospital de Cancer de Barretos - Fundacao Pio XII"},{"orgOrder":0,"company":"Amylynne Frankel","sponsor":"Graceway Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Imiquimod","moa":"Toll-like receptor 7","graph1":"Dermatology","graph2":"Phase IV","graph3":"Amylynne Frankel","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amylynne Frankel \/ Graceway Pharmaceuticals","highestDevelopmentStatusID":"11","companyTruncated":"Amylynne Frankel \/ Graceway Pharmaceuticals"},{"orgOrder":0,"company":"CARE","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Imiquimod","moa":"||Toll-like receptor 7","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"CARE","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CARE \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"CARE \/ Undisclosed"}]

Find Clinical Drug Pipeline Developments & Deals for Imiquimod

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Barretos Cancer Hospital

                          Country arrow
                          Aus. Peptide Conference
                          Not Confirmed

                          Barretos Cancer Hospital

                          Country arrow
                          Aus. Peptide Conference
                          Not Confirmed

                          Lead Product(s) : Imiquimod

                          Therapeutic Area : Oncology

                          Study Phase : Phase IV

                          Sponsor : FAPESP | Farmoquimica | Hospital de Cancer de Barretos - Fundacao Pio XII

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Imiquimod is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Squamous Intraepithelial Lesions.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          April 10, 2024

                          Lead Product(s) : Imiquimod

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase IV

                          Sponsor : FAPESP | Farmoquimica | Hospital de Cancer de Barretos - Fundacao Pio XII

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          Aus. Peptide Conference
                          Not Confirmed
                          Aus. Peptide Conference
                          Not Confirmed

                          Details : Submission of an IND application to U.S. FDA in support of the planned initiation of Phase I clinical study for its anti-CTLA4 antibody, UGN-301 (zalifrelimab), investigational immunotherapy designed for monotherapy and combination therapy in treating lo...

                          Product Name : Undisclosed

                          Product Type : Antibody, Unconjugated

                          Upfront Cash : Inapplicable

                          March 01, 2022

                          Lead Product(s) : Zalifrelimab,Imiquimod

                          Therapeutic Area : Oncology

                          Highest Development Status : IND Enabling

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          Aus. Peptide Conference
                          Not Confirmed
                          Aus. Peptide Conference
                          Not Confirmed

                          Details : The collaboration aims to advance combinatorial intravesical immunotherapy, UGN-201 (imiquimod), a TLR 7/8 agonist and UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, for the treatment of HG-NMIBC.

                          Product Name : Undisclosed

                          Product Type : Antibody, Unconjugated

                          Upfront Cash : Undisclosed

                          January 13, 2021

                          Lead Product(s) : Zalifrelimab,Imiquimod

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : The University of Texas MD Anderson Cancer Center

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          04

                          CARE

                          Country arrow
                          Aus. Peptide Conference
                          Not Confirmed

                          CARE

                          Country arrow
                          Aus. Peptide Conference
                          Not Confirmed

                          Details : Clinical trial of immunomodulators combining Imiquimod and Hydroxychloroquine to prevent and treat early COVID-19 infection.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          May 04, 2020

                          Lead Product(s) : Imiquimod,Hydroxychloroquine Sulphate

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Undisclosed

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          Aus. Peptide Conference
                          Not Confirmed
                          Aus. Peptide Conference
                          Not Confirmed

                          Details : Imiquimod is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Breast Neoplasms.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          June 11, 2019

                          Lead Product(s) : Imiquimod

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Merck & Co

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          Icahn School of Medicine at Mount Sinai

                          Country arrow
                          Aus. Peptide Conference
                          Not Confirmed

                          Icahn School of Medicine at Mount Sinai

                          Country arrow
                          Aus. Peptide Conference
                          Not Confirmed

                          Details : Imiquimod is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Keratosis, Actinic.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          April 16, 2019

                          Lead Product(s) : Imiquimod

                          Therapeutic Area : Dermatology

                          Highest Development Status : Phase II

                          Sponsor : Bausch Health

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          Barretos Cancer Hospital

                          Country arrow
                          Aus. Peptide Conference
                          Not Confirmed

                          Barretos Cancer Hospital

                          Country arrow
                          Aus. Peptide Conference
                          Not Confirmed

                          Details : Imiquimod is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Intraepithelial Neoplasia.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          July 28, 2017

                          Lead Product(s) : Imiquimod

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Farmoquimica

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          Melanoma and Skin Cancer Trials Limited

                          Country arrow
                          Aus. Peptide Conference
                          Not Confirmed

                          Melanoma and Skin Cancer Trials Limited

                          Country arrow
                          Aus. Peptide Conference
                          Not Confirmed

                          Details : Imiquimod is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Hutchinson's Melanotic Freckle.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          March 20, 2015

                          Lead Product(s) : Imiquimod

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Sponsor : Melanoma Institute Australia

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          Maastricht University Medical Center

                          Country arrow
                          Aus. Peptide Conference
                          Not Confirmed

                          Maastricht University Medical Center

                          Country arrow
                          Aus. Peptide Conference
                          Not Confirmed

                          Details : Imiquimod is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Uterine Cervical Dysplasia.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          December 31, 2014

                          Lead Product(s) : Imiquimod

                          Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                          Highest Development Status : Phase III

                          Sponsor : Viatris

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          AIDS Malignancy Consortium

                          Country arrow
                          Aus. Peptide Conference
                          Not Confirmed

                          AIDS Malignancy Consortium

                          Country arrow
                          Aus. Peptide Conference
                          Not Confirmed

                          Lead Product(s) : Imiquimod

                          Therapeutic Area : Oncology

                          Study Phase : Phase III

                          Sponsor : National Cancer Institute | The Emmes Company, LLC | University of Arkansas | University of California, San Francisco | University of Arizona

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Imiquimod is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Anus Neoplasms.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          May 12, 2014

                          Lead Product(s) : Imiquimod

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Sponsor : National Cancer Institute | The Emmes Company, LLC | University of Arkansas | University of California, San Francisco | University of Arizona

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank